Thermo Fisher
NYSE: TMO · Health Care · Life Sciences Tools & Services · WALTHAM, MA
Largest supplier of lab instruments, reagents and consumables, and a contract development and clinical-research (PPD) services provider to pharma.
Annual results
Click any number to open the SEC filing it came from.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B |
| Net income | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B |
| EPS — diluted | $19.46 per share | $17.63 per share | $15.45 per share | $16.53 per share | $17.74 per share |
| Cash from operations | $9.3B | $9.2B | $8.4B | $8.7B | $7.8B |
| Free cash flow | $6.8B | $6.9B | $6.9B | $7.3B | $6.3B |
| Total assets | $95.1B | $97.2B | $98.7B | $97.3B | $110.3B |
Recent filings
Members see much more
The full TMO file, with an AI analyst on it.
- Quarterly statements, segments and IR data
- Valuation, earnings and insider activity
- A research assistant that cites the filing sentence